Prodrugs of the Archetypal Dynamin Inhibitor Bis-T-22

Odell, Luke R., Robertson, Mark J., Young, Kelly A., Mcgeachie, Andrew B., Quan, Annie, Robinson, Phillip J., and McCluskey, Adam (2022) Prodrugs of the Archetypal Dynamin Inhibitor Bis-T-22. ChemMedChem, 17 (24). e202200400.

[img]
Preview
PDF (Published Version) - Published Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (2MB) | Preview
View at Publisher Website: https://doi.org/10.1002/cmdc.202200400
 
411


Abstract

The Bis-T series of compounds comprise some of the most potent inhibitors of dynamin GTPase activity yet reported, e. g., (2E,2′E)-N,N′-(propane-1,3-diyl)bis(2-cyano-3-(3,4-dihydroxyphenyl)acrylamide) (2), Bis-T-22. The catechol moieties are believed to limit cell permeability, rendering these compounds largely inactive in cells. To solve this problem, a prodrug strategy was envisaged and eight ester analogues were synthesised. The shortest and bulkiest esters (acetate and butyl/tert-butyl) were found to be insoluble under physiological conditions, whilst the remaining five were soluble and stable under these conditions. These five were analysed for plasma stability and half-lives ranged from ∼2.3 min (propionic ester 4), increasing with size and bulk, to greater than 24 hr (dimethyl carbamate 10). Similar profiles where observed with the rate of formation of Bis-T-22 with half-lives ranging from ∼25 mins (propionic ester 4). Propionic ester 4 was chosen to undergo further testing and was found to inhibit endocytosis in a dose-dependent manner with IC50 ∼8 μM, suggesting this compound is able to effectively cross the cell membrane where it is rapidly hydrolysed to the desired Bis-T-22 parent compound.

Item ID: 76858
Item Type: Article (Research - C1)
ISSN: 1860-7187
Keywords: dynamin, endocytosis, prodrug, Bis-T-22
Copyright Information: © 2022 The Authors. ChemMedChem published by Wiley-VCH GmbH. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Date Deposited: 23 Nov 2022 08:28
FoR Codes: 32 BIOMEDICAL AND CLINICAL SCIENCES > 3214 Pharmacology and pharmaceutical sciences > 321402 Clinical pharmacology and therapeutics @ 100%
SEO Codes: 20 HEALTH > 2001 Clinical health > 200105 Treatment of human diseases and conditions @ 100%
Downloads: Total: 411
Last 12 Months: 6
More Statistics

Actions (Repository Staff Only)

Item Control Page Item Control Page